Literature DB >> 6497463

Fibrin(ogen)olysis in polymyalgia rheumatica and temporal arteritis: preliminary findings on association with disease activity.

R G Grau, S S Kassan, J J Franks, H Kaplan, S H Walker, E M Tan.   

Abstract

Postulating an increased production of fibrin(ogen)olytic degradation products (FDP) and an abnormality of fibrinogen metabolism in polymyalgia rheumatica (PMR) and temporal arteritis (TA), we studied 16 PMR/TA patients and 10 control subjects using a sensitive radioimmunoassay for a specific type of FDP, namely, fibrin(ogen)-related D-antigen. Median serum D-antigen levels were increased five-fold in those 11 PMR/TA patients who were untreated compared with control subjects. In the five PMR/TA patients who were treated with prednisone the median D-antigen levels were not significantly different from those of the healthy controls. D-antigen concentration correlated significantly (r = 0.83) with ESR in the seven untreated PMR patients. In PMR patients prednisone therapy was followed by a reduction of serum D-antigen levels.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6497463      PMCID: PMC1001515          DOI: 10.1136/ard.43.5.721

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  13 in total

1.  High molecular weight derivatives of human fibrinogen produced by plasmin. I. Physicochemical and immunological characterization.

Authors:  V J Marder; N R Shulman; W R Carroll
Journal:  J Biol Chem       Date:  1969-04-25       Impact factor: 5.157

2.  Polymyalgia rheumatica.

Authors:  G G Hunder; T F Disney; L E Ward
Journal:  Mayo Clin Proc       Date:  1969-12       Impact factor: 7.616

3.  Specific and sensitive determination of fibrinogen-degradation products by radioimmunoassay.

Authors:  Y B Gordon; M J Martin; A T McNeile; T Chard
Journal:  Lancet       Date:  1973-11-24       Impact factor: 79.321

4.  Letter: The fibrinogenolytic pathway of fibrinogen catabolism: a reply.

Authors:  D Collen; N Semeraro; M Verstraete
Journal:  Thromb Res       Date:  1974-03       Impact factor: 3.944

5.  Temporal arteritis and polymyalgia rheumatica. Clinical and biopsy findings.

Authors:  P Fauchald; O Rygvold; B Oystese
Journal:  Ann Intern Med       Date:  1972-12       Impact factor: 25.391

Review 6.  Giant cell arteritis: including temporal arteritis and polymyalgia rheumatica.

Authors:  C R Hamilton; W M Shelley; P A Tumulty
Journal:  Medicine (Baltimore)       Date:  1971-01       Impact factor: 1.889

7.  A rapid, simple, sensitive method for measuring fibrinolytic split products in human serum.

Authors:  C Merskey; P Lalezari; A J Johnson
Journal:  Proc Soc Exp Biol Med       Date:  1969-07

8.  Enhanced thrombin and plasmin activity with exercise in man.

Authors:  T M Hyers; B J Martin; D S Pratt; R B Dreisin; J J Franks
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1980-05

9.  Polymyalgia rheumatica. A manifestation of systemic giant-cell arteritis.

Authors:  K R Wilske; L A Healey
Journal:  Ann Intern Med       Date:  1967-01       Impact factor: 25.391

10.  Isolation of fibrinogen-fibrin related antigen from human plasma by immuno-affinity chromatography: its characterization in normal subjects and in defibrinating patients with abruptio placentae and disseminated cancer.

Authors:  C Merskey; A J Johnson; J U Harris; M T Wang; S Swain
Journal:  Br J Haematol       Date:  1980-04       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.